Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity, Inc. RVTY is well-positioned for growth, thanks to its strong product portfolio. The company benefits from a strong diagnostics franchise driven by newborn screening, TB testing and specialty immunodiagnostics, complemented by the rapid expansion of its high-margin Signals Software business. However, near-term challenges persist, including China’s reimbursement reforms pressuring immunodiagnostics, weak academic/government demand limiting instrumentation growth and exposure to macroeconomic and FX volatility.

This Zacks Rank #3 (Hold) company’s shares have gained 12% in the past six months compared with the industry’s 6.4% growth. The S&P 500 has jumped 7.2% during the same time frame.

The renowned provider of health science solutions has a market capitalization of $10.69 billion. It projects 8.7% growth over the next five years and expects to witness continued improvement in its business going forward. Revvity’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 4.13%.

Let’s delve deeper.

Upsides

Diagnostics Momentum and Resilient Core Segments: Revvity exited 2025 with strong momentum in its Diagnostics business, which delivered 7% organic growth in the fourth quarter, supported by robust performance in reproductive health, immunodiagnostics and newborn screening. Newborn screening continued to grow in the mid-single digits quarterly and high-single digits annually, outperforming underlying birth-rate trends through improved commercial execution and collaborations such as Genomics England. This resilient diagnostics portfolio provides a stable revenue base and recurring demand profile, positioning Revvity to sustain steady growth even amid volatile research spending cycles.

Expanding Software Ecosystem and AI-Driven Platforms: Revvity’s Signals software franchise is emerging as a key long-term growth lever, with high-teens organic growth in 2025, expanding SaaS adoption and more than 110% net retention rates. The launch of AI-enabled solutions like Signals Xynthetica, combined with integrations from the ACD/Labs acquisition, strengthens Revvity’s position in digital drug discovery workflows. Management expects these tools to accelerate preclinical research through AI-assisted modeling integrated directly into laboratory workflows. As the installed base across global pharma customers expands, the platform could drive higher recurring software revenue and cross-selling opportunities.

Strong Cash Generation and Capital Allocation Discipline: Revvity’s financial profile remains robust, highlighted by $515 million in free cash flow in 2025 with 87% conversion of adjusted net income and a manageable leverage ratio of 2.7 net debt to EBITDA. The company has also executed aggressive shareholder returns, repurchasing more than $800 million in shares in 2025 and more than $1.5 billion since mid-2023, reducing the share count meaningfully. Combined with ongoing cost-efficiency initiatives expected to lift operating margins to 28% in 2026, strong cash generation enhances Revvity’s ability to fund M&A, innovation and shareholder returns simultaneously.

Downsides

Muted Organic Growth Outlook Reflects Fragile End Markets: Despite a strong fourth-quarter finish, Revvity has guided only 2–3% organic growth for 2026, reflecting continued caution around biopharma and academic research spending. Management noted that many key end markets—particularly preclinical research and academic funding—remain uncertain after several years of pressure. This conservative outlook indicates that demand recovery in life sciences instrumentation and reagents may remain gradual, limiting near-term revenue acceleration and keeping overall growth below historical industry levels.

China Diagnostics Weakness and Policy Uncertainty: Revvity continues to face structural headwinds in China, particularly in immunodiagnostics, where double-digit declines were recorded during 2025 due to DRG-related volume pressures. Management now expects the business to remain slightly down in the second half of 2026, reflecting persistent uncertainty around healthcare policy changes and reimbursement dynamics. While China represents less than 5% of total company revenue, ongoing regulatory unpredictability and volume pressure could continue to dampen segment growth and limit upside in the Diagnostics portfolio.

Margin Pressures From Tariffs, FX and Operational Timing: Revvity’s profitability has recently been affected by multiple external factors, including tariffs, foreign-exchange fluctuations and lower volume leverage, which pushed full-year operating margins down to 27.1% in 2025. Although cost-efficiency programs are expected to restore margins toward 28% in 2026, near-term volatility remains likely. The company also expects weaker margins in early 2026 due to the implementation timing of cost initiatives and an additional operating week in the first quarter, suggesting uneven margin progression across the year.

Estimate Trend

Revvity has been witnessing an improving estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has improved 1.3% to $5.39.

The Zacks Consensus Estimate for first-quarter 2026 revenues is pegged at $700.9 million, indicating a 5.5% improvement from the year-ago reported number. The Zacks Consensus Estimate for EPS is pinned at $1.02, implying a year-over-year gain of 1%.

Revvity Inc. Price

Revvity Inc. price | Revvity Inc. Quote

Stocks to Consider

Some better-ranked stocks from the same medical industry are Globus Medical GMED, Pacific Biosciences of California PACB and Edwards Lifesciences EW.

Globus Medical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted EPS of $1.28, beating the Zacks Consensus Estimate by 20.8%. Revenues of $826 million surpassed the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, with the average surprise being 13.2%.

Pacific Biosciences of California, currently flaunting a Zacks Rank of 1, reported a fourth-quarter 2025 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $45 million beat the Zacks Consensus Estimate by 9.4%.

PACB has an estimated earnings decline rate of 1.9% against the industry’s 11.4% improvement. The company beat earnings estimates in the trailing four quarters, with the average surprise being 27.7%.

Edwards Lifesciences, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of 58 cents, which missed the Zacks Consensus Estimate by 6.5%. Revenues of $1.57 billion beat the Zacks Consensus Estimate by 2%.

EW has an estimated long-term earnings growth rate of 12.9% compared with the industry’s 14% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 5.5%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research